Panagiotis A. Konstantinopoulos, MD, PhD

Panagiotis A. Konstantinopoulos is the director of the Mellen and Eisenson Family Center for BRCA and Related Genes, director of Translational Research in the Division of Gynecologic Oncology, and the Velma Eisenson Endowed Chair for Clinical and Translational Research at Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School.

Articles

Optimized Immunotherapy Use and Novel Therapeutic Targets Move the Needle for Endometrial Cancer Management: With Ursula A. Matulonis, MD; and Panagiotis (Panos) A. Konstantinopoulos, MD, PhD

December 11th 2025

Drs Matulonis and Konstantinopoulos discuss the different subtypes of endometrial cancer and treatment developments for this disease.

Dr Konstantinopoulos on the Safety of Letrozole, Abemaciclib, and Metformin in ER+ Recurrent Endometrial Cancer

May 19th 2025

Panagiotis A. Konstantinopoulos, MD, PhD, discusses the safety of letrozole, abemaciclib, and metformin in ER-positive, recurrent endometrial cancer.

Dr Konstantinopoulos on Responses With Metformin Plus Letrozole/Abemaciclib in ER+ Endometriod Endometrial Cancer

April 9th 2025

Panagiotis A. Konstantinopoulos, MD, PhD, discusses CRs achieved with letrozole, abemaciclib, and metformin in ER–positive endometriod endometrial cancer.

Dr. Konstantinopoulos on Immunotherapy in Ovarian Cancer

March 8th 2019

Panagiotis A. Konstantinopoulos, MD, PhD, director of Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the role of immunotherapy in the treatment of patients with ovarian cancer.

Dr. Konstantinopoulos on Immunotherapy in Gynecologic Cancers

December 15th 2018

Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses immunotherapy in gynecologic cancers.

Dr. Konstantinopoulos Discusses PARP Plus Immunotherapy

September 22nd 2018

Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the combination of PARP inhibitors and immunotherapy.

Dr. Konstantinopoulos on Rationale for TOPACIO Trial in Ovarian Cancer

July 25th 2018

Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the rationale behind the TOPACIO trial for the treatment of patients with recurrent ovarian cancer.